Midterm Outcomes From a Pilot Study of Percutaneous Deep Vein Arterialization for the Treatment of No-Option Critical Limb Ischemia
  • About CLTI
  • Technology
    • Products
  • Clinical Evidence
    • ALPS Post-Market Study
    • PROMISE I Study Results
    • First-in-Human Study Results
    • Publications
  • U.S. Clinical Trial
  • Company
    • Management
    • Clinical Advisors
    • News
    • Articles
  • Contact
  • International
June 6 2017

Midterm Outcomes From a Pilot Study
of Percutaneous Deep Vein Arterialization
for the Treatment of No-Option
Critical Limb Ischemia

View the article.

LimFlow Expands Senior Management Team and Opens Silicon Valley Office LimFlow Announces First Patient Treated in U.S. Feasibility Study and Commencement of International Post-Market Study

Related Posts

News

LimFlow System Demonstrates Excellent Sustained Amputation-Free Survival and Wound Healing at One Year in PROMISE I U.S. Study

News

Publication of Two-Year Outcomes for LimFlow System Shows Excellent Amputation-free Survival and Wound Healing in Patients With No-Option Chronic Limb-Threatening Ischemia

News

First Patient Enrolled in PROMISE II U.S. Pivotal Study of LimFlow System to Treat Chronic Limb-Threatening Ischemia

Recent Posts

  • LimFlow System Demonstrates Excellent Sustained Amputation-Free Survival and Wound Healing at One Year in PROMISE I U.S. Study
  • Publication of Two-Year Outcomes for LimFlow System Shows Excellent Amputation-free Survival and Wound Healing in Patients With No-Option Chronic Limb-Threatening Ischemia
  • First Patient Enrolled in PROMISE II U.S. Pivotal Study of LimFlow System to Treat Chronic Limb-Threatening Ischemia
  • LimFlow Announces Positive Six-month Data From PROMISE I U.S. Early Feasibility Study Demonstrating Excellent Amputation Free Survival and Wound Healing in No-option Patient Population
  • Limflow Receives FDA Approval for U.S. Pivotal Study of Minimally-Invasive Technology Designed to Prevent Amputations in Chronic Limb-Threatening Ischemia Patients
LimFlow
CAUTION: Investigational device. Limited by Federal law to investigational use.:
The LimFlow System is approved for sale in markets regulated by the CE Mark.
©2020 LimFlow SA | Site designed by The Deciding Factor, Inc.